Conference Correspondent

In 2016, approximately 18,960 Americans were estimated to be diagnosed with chronic lymphocytic leukemia (CLL), and 4660 were estimated to die from the disease.
Elderly patients with chronic lymphocytic leukemia (CLL) and younger patients with comorbidities often receive treatment with chlorambucil despite the relative low response rates.
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) occur mainly in older patients, who are likely to have several comorbidities and who often are unable to receive aggressive drug therapies, such as alkylating drugs, which are typically used for patients with CLL or SLL.
In the long-term, phase 1b/2 PCYC-1102 clinical trial, single-agent ibrutinib, the first FDA-approved once-daily Bruton’s tyrosine kinase inhibitor, showed efficacy and good tolerability in patients with chronic lymphocytic leukemia (CLL) or with small lymphocytic lymphoma (SLL), including patients with deletion (del)17p.
Anticancer drugs should be priced based on the value they deliver to patients, according to Peter B. Bach, MD, Physician, Epidemiologist, Researcher, and Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center, New York.
Pharmacy-led oral chemotherapy programs lead to improved patient adherence and satisfaction, according to Benyam Muluneh, PharmD, BCOP, CPP, Oncology Clinical Pharmacist Practitioner, University of North Carolina (UNC) Medical Center, Malignant Hematology Clinic, Chapel Hill.
Patients with diffuse large B-cell lymphoma (DLBCL) are at increased risk for cardiovascular (CV) events, particularly during the first year following diagnosis, and these events shorten their lives, according to a retrospective study.
More than 1000 oncology nurse and patient navigators from across the United States and Canada gathered in Las Vegas for the Academy of Oncology Nurse & Patient Navigators (AONN+) Seventh Annual Navigation & Survivorship Conference.
American healthcare is in flux, and it is not just the drugs that are changing.
Prospective, observational, and multicenter trials have documented a dramatic increase in venous thromboembolism (VTE) in children with cancer over the past decade.
Page 2 of 29
Results 11 - 20 of 287